Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide after AcDVP16 in AML and high-risk MDS
NCT02029950Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2013
- Primary completion
- May 2020
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label trial of pomalidomide in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and 1 more, sponsored by National Cancer Institute. Started Dec 2013; status: completed.
02
Drugs
pomalidomide
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT02029950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02029950.